The 5-Second Trick For Z-LEHD-fmk
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze to evaluate various intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Main trial aims were To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis indivi